

# Glucagon regulation of carbohydrate metabolism in rainbow trout: *in vivo* glucose fluxes and gene expression

Johnathon L.I. Forbes, Daniel J. Kostyniuk, Jan A. Mennigen and Jean-Michel Weber

Biology Department, University of Ottawa, Ottawa, Ontario, Canada

## Address correspondence to:

Jean-Michel Weber  
Biology, University of Ottawa  
30 Marie Curie, Ottawa, Ontario  
Canada K1N 6N5  
E-mail: [jmweber@uOttawa.ca](mailto:jmweber@uOttawa.ca)  
Phone: (613) 562 - 5800 ext. 6007  
Fax : (613) 562 - 5486

## Summary statement

Glucagon causes hyperglycemia in rainbow trout by increasing hepatic glucose production via activation of gluconeogenesis, and by decreasing glucose disposal via inhibition of glycogen synthesis and glycolysis.

## Abstract

Glucagon increases fish glycemia, but how it affects glucose fluxes *in vivo* has never been characterized. The goal of this study was to test the hypothesis that glucagon stimulates hepatic glucose production ( $R_a$ ) and inhibits disposal ( $R_d$ ) of rainbow trout. Changes in the mRNA abundance of key proteins involved in glycolysis, gluconeogenesis, and glycogen breakdown were also monitored. Results show that glucagon increases glycemia (+38%) by causing a temporary mismatch between  $R_a$  and  $R_d$  before both fluxes converge below baseline (-17%). A novel aspect of the regulation of trout gluconeogenesis is also demonstrated: the completely different effects of glucagon on the expression of three Pepck isoforms (stimulation of *pck1*, inhibition of *pck2a*, and no response of *pck2b*). Glycogen phosphorylase was modulated differently among tissues, and muscle upregulated *pygb* and downregulated *pygm*. Glucagon failed to activate the cAMP-dependent protein kinase or FoxO1 signalling cascades. We conclude that trout hyperglycemia results from the combination of two responses: (i) an increase in  $R_a$  glucose induced by the stimulation of gluconeogenesis through transcriptional activation of *pck1* (and possibly glycogen phosphorylase), and (ii) a decrease in  $R_d$  glucose via inhibition of glycogen synthase and glycolysis. The observed decrease in glucose fluxes after 4 h of glucagon administration may be caused by a counterregulatory response of insulin, potentially linked to the decrease in *pygm* transcript abundance. Overall, however, these integrated effects of glucagon only lead to modest changes in glucose fluxes that partly explain why trout seem to be unable to control glycemia very tightly.

**Key words:** fish glucoregulation, glucose production and disposal, gluconeogenesis, glycogen, glucagon signalling.

## Introduction

The regulation of circulating glucose levels is necessary for adequate fuel supply to the brain and working muscles (Shrayyef and Gerich, 2010; Wasserman et al., 2011), but fish do not generally control glycemia as tightly as birds or mammals (Enes et al., 2009; Polakof et al., 2012). Blood glucose concentration depends on changing rates of hepatic production ( $R_a$  glucose) and peripheral disposal ( $R_d$  glucose)(Weber et al., 2016). Although thoroughly characterized in mammals (Wasserman, 2009), the hormonal regulation of glucose fluxes remains poorly explored in fish. Only two previous studies have addressed this issue by examining how epinephrine (Weber and Shanghavi, 2000) and insulin (Forbes et al., 2019) regulate fish glucose kinetics. The catabolic hormone glucagon is another important endocrine signal that controls glucose fluxes in mammals, and possibly also in fish (Polakof et al., 2012; Shrayyef and Gerich, 2010). Multiple metabolic responses to glucagon have been demonstrated in mammals where it stimulates glucose production, and weakly inhibits (Lins et al., 1983), or has no effect on glucose disposal (Hinshaw et al., 2015). Glucagon increases glycemia in fish (Polakof et al., 2012), but this response could be mediated through an increase in  $R_a$ , a decrease in  $R_d$ , or a combination of both. Current information suggests that fish  $R_a$  glucose is probably stimulated by glucagon because gluconeogenic and glycogenolytic enzymes are upregulated in isolated hepatocytes (Brighenti et al., 1991; Foster and Moon, 1990; Puviani et al., 1990; Sugita et al., 2001). Several studies also support the idea that fish  $R_d$  glucose could be inhibited because glucagon decreases liver activities of glycogen synthase (Murat and Plisetskaya, 1977), phosphofructokinase (Foster et al., 1989) and pyruvate kinase (Petersen et al., 1987). However, *in vivo*

measurements of glucose kinetics are necessary to establish how glucagon-induced changes in  $R_a$  and  $R_d$  glucose cause an increase in fish glycemia.

The effects of glucagon on glucose metabolism are mediated by two pathways: cyclic AMP (cAMP) and calcium signalling. Glucagon binds to the G-protein-coupled receptor that raises GTP, causing increases in cAMP and inositol trisphosphate ( $IP_3$ ) (Moon et al., 1997). Then, the cAMP and calcium signalling pathways are mobilized to activate cAMP-dependent protein kinase (PKA) which, in turn, regulates several downstream targets (PKA substrates) (Plisetskaya and Mommsen, 1996), and possibly also FoxO1 as in mammals (Eijkelenboom and Burgering, 2013). Phosphorylated forms of PKA substrates and FoxO1 are associated with the regulation of metabolic processes that include gluconeogenesis and glycogen breakdown (Habegger et al., 2010; Moon, 1998), but whether glucagon causes phosphorylation of these targets has not been determined for fish. In particular, It would be useful to know if liver and muscle are affected because these two tissues play essential roles in glucose metabolism.

The main goal of this study was to test the hypothesis that glucagon-induced fish hyperglycemia is caused by stimulating glucose production and inhibiting glucose disposal as it does in mammals. We anticipated that glucagon would have a weaker effect on fish glucose production because fish generally have a lower capacity for glucoregulation. Other goals were: (i) to measure levels of phosphorylated PKA substrates and FoxO1 in muscle and liver to determine whether these signalling cascades are activated, and (ii) to monitor potential changes in transcript levels of key proteins involved in glycolysis, gluconeogenesis, glycogen mobilization, and transmembrane glucose transport. Because salmonids have experienced several whole genome duplications in their evolutionary history

(Berthelot et al., 2014), we have quantified the mRNA expression of multiple paralogs of phosphoenolpyruvate carboxykinase (Pepck) and glycogen phosphorylase (Gp) that could show different responses to glucagon.

## **Methods**

### ***Animals***

Adult rainbow trout (*Oncorhynchus mykiss*) of both sexes were purchased from Linwood Acres Trout Farm (Campbellcroft, Ontario, Canada). All results presented are pooled male and female values because no significant sex differences were observed for the measured parameters of this study. Two groups of fish were used: (i) for *in vivo* measurements of glucose kinetics, and (ii) for measurements of gene expression of mRNA (qPCR) and glucagon signalling proteins (Western blots). The physical characteristics of each experimental group are given in Table 1. The fish were held in a 1,200 liter flow-through tank supplied with dechloraminated Ottawa tap water at 13°C, on a 12 h:12 h light:dark photoperiod and they were fed Profishnet floating fish pellets (Martin Mills, Elmira, ON, Canada) 5 days a week. They were acclimated to these conditions for a minimum of 2 weeks before experiments. All the procedures were approved by the Animal Care Committee of the University of Ottawa and adhered to the guidelines established by the Canadian Council on Animal Care.

### ***Catheterizations and respirometry***

Fish were anesthetized with ethyl 3-aminobenzoate methanesulfonate (MS-222 at a concentration of 60 mg l<sup>-1</sup> buffered with 0.2 g l<sup>-1</sup> sodium bicarbonate) and surgically fitted with 2 catheters (for glucose kinetics experiments) or a single catheter (for signalling protein and gene expression experiments)(BTPE-50 catheters, Instech Laboratories, Plymouth Meeting, PA, USA) in the dorsal aorta (Haman and Weber, 1996). The catheters were kept patent by flushing with Cortland saline containing 50 U ml<sup>-1</sup> heparin (Sigma-Aldrich, St Louis, MO, USA). After surgery, the fish were left to recover overnight in a 90 liter swim-tunnel respirometer (Loligo Systems, Tjele, Denmark) where all the *in vivo* measurements were carried out in resting animals at a water velocity of 0.5 body length per second (BL s<sup>-1</sup>). This weak current reduces stress and enhances the flow of water over the gills, but it does not require swimming to maintain body position because the animals are sitting at the bottom of the respirometer chamber (Choi and Weber, 2015). The respirometer was supplied with the same quality water as the holding tank and was kept at 13°C.

### ***Glucose kinetics experiments***

The catheters were made accessible through the respirometer lid by channeling them through a water-tight port. The rates of glucose turnover ( $R_t$ ), hepatic glucose production ( $R_a$ ) and glucose disposal ( $R_d$ ) were measured by continuous infusion of [6-<sup>3</sup>H]glucose (Perkin Elmer, Boston, MA, USA; specific activity 222 GBq mmol<sup>-1</sup>) in a group of 8 fish (see Table 1). This tracer method has been validated to quantify glucose kinetics in fish (Haman et al., 1997a) and

thoroughly tested in rainbow trout under a variety of physiological stresses (Choi and Weber, 2016; Haman et al., 1997b; Shanghavi and Weber, 1999; Weber et al., 2016). The infusate was freshly prepared immediately before each experiment by drying an aliquot of the solution obtained from the supplier under N<sub>2</sub> and resuspending in Cortland saline. A priming dose of tracer equivalent to 3 h of infusion was injected as a bolus at the start of each infusion to reach isotopic steady state in <45 min. The infusate was then administered continuously at ~1 ml/h (exact infusion rates were determined individually for each fish to correct for differences in body mass) using a calibrated syringe pump (Harvard Apparatus, South Natick, MA). Infusion rates for labeled glucose averaged 2007 ± 181 Bq kg<sup>-1</sup> min<sup>-1</sup> (N=8) and these trace amounts of glucose (labeled and unlabeled) had no effect on glucose metabolism because they only accounted for 0.00001% of the baseline endogenous rate of hepatic glucose production. Blood samples (~100 µl each) were drawn 50, 55 and 60 min after starting the tracer infusion to determine baseline glucose kinetics, and every 20 min thereafter during glucagon administration (8.3 µg bovine glucagon kg<sup>-1</sup> min<sup>-1</sup> for 4 h at 1 ml/h). Sham infusion of saline has no effect on glucose kinetics (see Fig. 2 in Weber and Shanghavi, 2000). Values measured before the start of glucagon infusion were therefore used as baseline. Bovine glucagon has been commonly used to investigate the effects of teleost glucagon (Foster and Moon, 1990; Foster et al., 1989; Plisetskaya and Mommsen, 1996). The rate of glucagon infusion selected was based on a previous study where the hormone was also administered *in vivo* to rainbow trout and where it elicited significant changes in glucose metabolism (de la Higuera and Cardenas, 1986). The total amount of blood sampled from each fish accounted for <10% of total blood volume. Samples were collected in tubes containing heparin and aprotinin (500 KIU ml<sup>-1</sup> to stabilize

glucagon). They were centrifuged to separate plasma (5 min; 12,000 RPM) that was stored at -20°C until analyses.

### ***Gene expression and signalling protein experiments***

To avoid making the measurements in radioactive tissues, these experiments were carried out on different fish than those used for glucose kinetics, but they received the same infusions: saline (control group) or glucagon (treatment group; 8.3  $\mu\text{g kg}^{-1} \text{min}^{-1}$ ) that were administered at 1 ml/h through the catheter for 4 h. Fourteen fish were used for these experiments (see Table 1). The animals were then euthanized by a sharp blow on the head before collecting the liver and ~4 g of white muscle (dorsal region, anteriorly to the dorsal fin). The tissue samples were stored at -80°C until analyses.

### ***Sample analyses***

Glucose kinetics: Plasma glucagon and glucose concentrations were measured spectrophotometrically using a Spectra Max Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). Glucagon was measured using a commercial ELISA kit (Crystal Chem, Downers Grove, IL). This kit uses a particular COOH-terminal anti-glucagon fragment that has been previously validated for measuring fish glucagon (Navarro et al., 1995). Unfortunately, fish insulin cannot be measured accurately at the present time (Moon, 2001). A radioimmunoassay was developed decades ago (Plisetskaya, 1998), but it also measures pro-insulins and, therefore, overestimates true insulin concentration. Glucose activity was quantified by drying plasma under  $\text{N}_2$  to eliminate tritiated water and by resuspending in distilled water. Radioactivity was then measured by



scintillation counting (Perkin-Elmer Tricarb 2910TR, Perkin-Elmer, Inc., Waltham, MA, USA) in Bio-Safe II scintillation fluid (RPI Corp., Mount Prospect, IL, USA).

mRNA transcript abundance: Total RNA was extracted from 20 to 100 mg of individual liver or muscle samples (N=7 per group) using TRIzol (Invitrogen, Burlington, ON, Canada) following the manufacturer's protocol. Tissues (control N=7; glucagon N=7) were homogenized using a sonicator Model 100 (Thermo-Fisher Scientific, Ottawa, ON, Canada) on ice until tissue fragments were no longer visible. Extracted RNA was quantified using a NanoDrop® 2000c UV-Vis Spectrophotometer (Thermo-Fisher Scientific). Next cDNA was generated from the total RNA using a QuantiTech Reverse Transcription Kit (Qiagen, Toronto, ON, Canada) following the manufacturer's protocol. Two step quantitative real-time RT-PCR assays were performed on a Bio-Rad CFX96 instrument (Bio-Rad, Mississauga, ON, Canada) to quantify fold changes in relative liver and muscle mRNA abundances of key transcripts involved in gluconeogenesis (*pck1*, *pck2a*, *pck2b*, *fbpase*), glycogenolysis (glycogen phosphorylase brain-associated *pygb*, glycogen phosphorylase muscle-associated *pygm*, *g6pase*), glycolysis (*pfk*) and glucose transport (*glut1*, *glut2*, *glut4*). A standard curve consisting of serial dilutions of pooled cDNA, a negative no-RT control consisting of cDNA generated in a reaction that did not include reverse transcriptase, a negative no-template control generated in a reaction that substituted water for RNA and individual diluted samples were run in duplicate. For each individual reaction, the total volume was 20 µl, that consisted of 4 µl diluted cDNA template, 0.5 µl 10 µM specific forward and 0.5 µl 10 µM specific reverse primer (Table 2), 10 µl SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) and 5 µl nuclease free H<sub>2</sub>O. For each assay, cycling parameters were a 2 min activation step at 98°C followed by 40 cycles consisting of a 20 sec denaturation step at 95°C and a

combined 30 sec annealing and extension step at primer specific temperatures (Table 2). Following each run, melting curves were produced (65°C – 95°C at 0.5°C every 5 seconds) by gradually increasing temperature and the final curves were monitored for single peaks to confirm the specificity of the reaction and the absence of primer dimers. In cases where primers were newly designed, pooled samples were sent for sequencing (Ottawa Hospital Research Institute, Ottawa, ON, Canada), followed by BLAST search (NCBI), to confirm amplicon specificity. The acceptable range for amplification efficiency calculated from serially diluted standard curves was 90-110% with  $R^2$  values  $>0.97$ . Assays were subsequently normalized using the NORMA-Gene approach as described by Heckmann et al. (Heckmann et al., 2011). Finally, mRNA fold-changes were calculated relative to the control group.

*Glucagon signalling proteins:* Frozen liver and muscle samples (control: N=7; glucagon: N=7; ~200 mg) were homogenized on ice with a sonicator (Fisher Scientific Sonic Dismembrator Model 100, San Diego, CA, USA) in 400  $\mu$ l of per 100 mg of tissue. During homogenization, samples were kept in a buffer containing 150  $\text{mmol l}^{-1}$  NaCl, 10  $\text{mmol l}^{-1}$  Tris, 1  $\text{mmol l}^{-1}$  EGTA, 1  $\text{mmol l}^{-1}$  EDTA (pH 7.4), 100  $\text{mmol l}^{-1}$  sodium fluoride, 4  $\text{mmol l}^{-1}$  sodium pyrophosphate, 2  $\text{mmol l}^{-1}$  sodium orthovanadate, 1% (v/v) Triton X-100, 0.5% (v/v) NP40-IGEPAL and a protease inhibitor cocktail (Roche, Basel, Switzerland). Homogenates were centrifuged at 15,000 g for 5 min at 4°C, the resulting supernatants were recovered and stored at -80°C. Protein concentrations were determined using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Munich, Germany) with BSA as standard. Lysates (200  $\mu$ g of total protein for liver and 50  $\mu$ g for muscle) were diluted in the previously described buffer and 2 $\times$  Laemmli. The prepared samples were denatured at 95°C for 2 min and quick chilled on ice before being subjected to SDS-PAGE and western blotting

using the appropriate antibodies (monoclonal rabbit anti-p-PKA substrates (RRXS\*/T\*) (9624; Cell Signaling Technology, Whitby, Canada) validated by (Dindia et al., 2012), and polyclonal rabbit anti-p-FOXO1 (9464; Cell Signaling Technology, Whitby, Canada) validated by (Cleveland and Weber, 2010; Seilliez et al., 2010), and were normalized using REVERT Total Protein Stain (LI-COR Biosciences, Lincoln, NE, USA). Gels were cast as 10% resolving gel consisting of 5 ml ddH<sub>2</sub>O, 2.5 ml buffer B pH 8.8 (1.5 M Tris base, 0.04% SDS; both BioShop, Burlington, ON, Canada) dissolved in dH<sub>2</sub>O, 2.5 ml 40% acryl/Bis (Bio-Rad, Mississauga, ON, Canada) and polymerized with 50 µl 10% APS (Sigma-Aldrich Oakville, ON, Canada) and 20 µl TEMED (Life Technologies Burlington, ON, Canada), and a 4% stacking gel [consisting of 3.25 ml ddH<sub>2</sub>O, 1.25 ml buffer C pH 6.8 (0.5 M Tris, 0.04% SDS dissolved (BioShop) in dH<sub>2</sub>O), 0.5 ml 40% acryl/bis polymerized with 25 µl 10% APS, and 10 µl TEMED. Gels were immersed in 1× Tris glycine SDS (TGS) running buffer, consisting of Tris base 2.5 mM, glycine 0.192 M, and 0.1% SDS (all BioShop Canada) dissolved in dH<sub>2</sub>O, and samples were loaded with 5 µl of Page Ruler prestained protein ladder (Thermo Fisher, Ottawa, ON, Canada). Proteins were migrated in the gel at 100 V. After migration, they were transferred onto nitrocellulose 0.45-mm pore size membrane paper (Millipore, Etobicoke, ON, Canada) by wet transfer using the Mini TransBlot system (Bio-Rad) with transfer buffer (250 mM Tris base, 1,920 mM glycine; all BioShop Canada) dissolved in dH<sub>2</sub>O, by applying 100 V for 2 h. Membranes were incubated with Odyssey blocking buffer (LI-COR Biosciences Lincoln, NE) for 1 h at room temperature using an orbital shaker was used to prevent nonspecific binding and then incubated in primary antibody at a concentration of 1:10,000 on an orbital shaker at 4°C overnight. Membranes were washed four times for 5 min with PBS + 0.1% TWEEN20 then

incubated with an IRDye Infrared secondary goat anti-rabbit IgG antibody (LIC-925-68071; LI-COR Biosciences, Lincoln, NE, USA). Bands were visualized by Infrared Fluorescence using the Odyssey Imaging System (LI-COR Biosciences) and quantified by Odyssey Infrared imaging system software (v.3.0, LI-COR Biosciences).

### ***Calculations and statistics***

Fulton's condition factor was computed as  $K = (10^5 \times M_b) / L^3$ ; where  $M_b$  = body mass in g and  $L$  = total length in mm (Blackwell et al., 2000). Glucose fluxes were calculated 2 ways, using either the steady-state or the non-steady-state equations of Steele (Forbes et al., 2019; Steele, 1959). Glucose turnover ( $R_t$ ) was calculated using the steady-state equation. Then, the non-steady-state equations were used to calculate  $R_a$  and  $R_d$  glucose separately after changes in specific activity over time were curve-fitted by 2<sup>nd</sup>-degree polynomial regression for each animal (see Wolfe, 1992) as described in more detail previously (Forbes et al., 2019). Statistical comparisons were performed using one-way repeated-measures analysis of variance (RM-ANOVA) with the Dunnett's post hoc test to determine which means were significantly different from baseline (SigmaPlot v12, Systat Software, San Jose, CA, USA). When the assumptions of normality or equality of variances were not met and if data transformations failed to normalize data distribution, Friedman's non-parametric RM-ANOVA on ranks was used. Gene expression and signalling protein data were analyzed using Mann-Whitney rank sum test. Values are presented as means  $\pm$  s.e.m. and a level of significance of  $P < 0.05$  was used in all tests.

## Results

### *Glucagon, glycemia, and glucose kinetics*

The administration of exogenous glucagon caused a steady increase in plasma glucagon concentration that became significantly higher than baseline after 2 h ( $P < 0.05$ ). Glucagon increased from a baseline value of  $18.6 \pm 2.0$  pg ml<sup>-1</sup> (N=8) to a final value of  $124.8 \pm 42.0$  ng ml<sup>-1</sup> (supplementary Fig. S1) after 4 h (N=8;  $P < 0.001$ ). Fig. 1 shows the changes in plasma glucose concentration and glucose specific activity before and during glucagon administration. Glucose concentration increased progressively for the first 3 h before reaching a plateau during the last hour of the experiment ( $P < 0.05$ ; Fig. 1A). Glucose specific activity showed no significant change from baseline ( $P > 0.05$ ; Fig. 1B). The effects of glucagon on glucose turnover rate ( $R_t$ ), hepatic glucose production ( $R_a$ ), glucose disposal ( $R_d$ ), and the capacity to increase glycemia [ $R_a$  glucose –  $R_d$  glucose] are presented in Fig. 2.  $R_t$  glucose showed no significant response to the hormone ( $P > 0.05$ ; Fig. 2A). Both  $R_a$  and  $R_d$  glucose remained constant for the first 2 h of glucagon infusion before decreasing progressively to reach a common final value lower than baseline ( $P < 0.05$ ; Fig. 2B). The capacity to increase glycemia [ $R_a$  glucose –  $R_d$  glucose] was stimulated to a maximum of  $1.5$   $\mu\text{mol kg}^{-1} \text{min}^{-1}$  during the first few minutes of glucagon infusion ( $P < 0.05$ ; Fig. 2C) before decreasing steadily to zero over the course of the experiment. Table 3 summarizes mean initial (baseline) and final values (after 4 h of glucagon infusion) for glucose concentration and fluxes.

## **Gene expression**

The effects of glucagon on muscle and liver mRNA abundance for key proteins of glucose metabolism are shown in Figs. 3 to 5. In muscle, glucagon caused an increase in the transcript abundance for glycogen phosphorylase, brain-associated (*pygb*) ( $P < 0.01$ ), but a decrease for glycogen phosphorylase, muscle-associated (*pygm*) ( $P < 0.05$ ; Fig. 3). In this tissue, no significant changes were observed for phosphofructokinase-1 (*pfk*), and glucose transporters 1 or 4 (*glut1*, *glut4*) ( $P > 0.05$ ; Fig. 3). In liver, the 3 isoforms of phosphoenolpyruvate carboxykinase responded differently to glucagon (Fig. 4). Phosphoenolpyruvate carboxykinase 1 (*pck1*) increased by 42-fold ( $P < 0.01$ ), phosphoenolpyruvate carboxykinase 2a (*pck2a*) decreased ( $P < 0.05$ ), and phosphoenolpyruvate carboxykinase 2b (*pck2b*) was not affected by the hormone ( $P > 0.05$ ; Fig. 4). The liver expressions for the other gluconeogenic enzymes fructose-bis-phosphatase (*fbpase*) and glucose-6-phosphatase (*g6pase*) as well as for glucose transporter 2 (*glut2*) and glycogen phosphorylase, brain associated (*pygb*) were not affected by glucagon ( $P > 0.05$ ; Fig. 5).

## **Glucagon signalling**

The effects of exogenous glucagon on the active (phosphorylated) form of PKA substrates and FoxO1 in muscle and liver are shown in Fig. 6. Glucagon did not significantly activate PKA substrates in muscle ( $P = 0.93$ ) or liver ( $P = 0.13$ ). Similarly, the hormone did not cause the activation of FoxO1 in either tissue (muscle:  $P = 0.21$ ; liver:  $P = 0.29$ ).

## Discussion

This study is the first to characterize the effects of glucagon on fish glucose fluxes *in vivo*. It shows that the hormone elicits hyperglycemia by causing a temporary mismatch between hepatic glucose production and peripheral glucose utilization that slowly disappears over 4 h. Both  $R_a$  and  $R_d$  glucose eventually decrease below baseline during the last 2 h of glucagon administration. Results also show a novel aspect of the regulation of trout gluconeogenesis: the completely different effects of glucagon on the expression of the three isoforms of Pepck: stimulation of *pck1*, inhibition of *pck2a*, and no response of *pck2b*. Furthermore, the transcript abundance of glycogen phosphorylase is modulated differently among tissues, or even within muscle that responds by upregulating *pygb* and downregulating *pygm*.

### ***Initial effects of glucagon on glucose fluxes***

Increasing circulating glucagon causes an initial divergence between  $R_a$  and  $R_d$  that raises blood glucose concentration by 38%. These immediate responses (stimulation of  $R_a$  and inhibition of  $R_d$ ) fail to reach statistical significance (Fig. 2B), but the divergence clearly occurs because hyperglycemia ensues (Fig. 1A), and the difference between  $R_a$  and  $R_d$  jumps significantly to  $1.5 \mu\text{mol kg}^{-1} \text{min}^{-1}$  immediately upon glucagon administration (Fig. 2C). Upregulating hepatic glucose production can be achieved by activating gluconeogenesis, glycogen breakdown or both. Previous fish studies show that glucagon stimulates gluconeogenesis by increasing Pepck activity (Foster and Moon, 1990) and by stimulating FBPase and G6Pase in isolated hepatocytes (Sugita et al., 2001). Similar responses have been documented for

mammals that increase the expression and activity of these same enzymes (Band and Jones, 1980; Beale et al., 1984; Christ et al., 1988; Pilkis et al., 1982; Striffler et al., 1984). Glucagon also stimulates glycogen breakdown by increasing glycogen phosphorylase activity by ~50% in trout (Puviani et al., 1990), and ~160% in mammals (Malbon et al., 1978). Observed changes in mRNA transcript abundance suggest that glucagon increases trout  $R_a$  glucose by upregulating gluconeogenesis as well as glycogen breakdown. However, mRNA abundance, protein abundance, and protein activity often show differential responses and direct measurements of protein activity will be needed to confirm this conclusion. The potential mechanisms involved in decreasing glucose disposal are not clear, but the inhibition of glycogen synthesis and hepatic glycolysis could be at play. Experiments on fish liver have shown that glucagon reduces the activities of glycogen synthase (Gs)(Murat and Plisetskaya, 1977), pyruvate kinase (*Pk*)(Petersen et al., 1987) and phosphofructokinase (*Pfk*)(Foster et al., 1989), similarly to what occurs in mammals (Jiang and Zhang, 2003). Overall, therefore, the glucagon-driven hyperglycemia is probably caused by a series of integrated, mostly hepatic responses including the stimulation of gluconeogenesis and glycogen phosphorylase, and the inhibition of glycolysis and glycogen synthase.

### ***Longer term effects of glucagon***

After 2 hours of glucagon infusion, blood glucose concentration stabilizes at ~12  $\mu\text{mol ml}^{-1}$  (Fig. 1A), rates of glucose production and disposal decrease progressively below baseline to converge to the same lower value (Fig. 2B), and the capacity to raise glycemia (measured as  $[R_a - R_d]$ ) is eventually reduced to zero (Fig.



2C). These longer-term changes suggest that exogenous glucagon triggers a counterregulatory response by insulin that prevents a further increase in circulating glucose concentration, and ultimately tries to restore normoglycemia. When fish experience hyperglycemia, glucosensing neurons and beta cells of the Brockmann bodies are known to stimulate insulin secretion (Blasco et al., 2001; de Celis et al., 2004; Furuichi and Yone, 1981; Ince, 1979). Raising insulin levels inhibits glucose production more strongly than glucose disposal (Forbes et al., 2019), and this could explain why  $[R_a - R_d]$  returns to zero during the last hour of our experiments (Fig. 2C). Whether a counterregulatory response actually takes place cannot presently be tested because measuring fish insulin accurately is not possible (Moon, 2001). A radioimmunoassay was developed more than 2 decades ago (Plisetskaya, 1998), but it also measures pro-insulin, and, therefore, overestimates true insulin concentration to some unknown and varying extent. Nevertheless, insulin is the most likely signal that could cause the decrease in glucose fluxes observed after 4 h of glucagon administration.

### ***Regulation of phosphoenolpyruvate carboxykinase (Pepck)***

This study shows that the 3 isoforms of trout hepatic Pepck respond very differently to glucagon (Fig. 5). The best characterized Pepck isoform (trout *Pck1* and mammalian *PEPCK-C*) is strongly stimulated by glucagon in fish (a more than 40-fold increase; top Fig. 4) as well as in mammals (Ilyedjian and Salavert, 1984). This cytosolic form of the enzyme is tightly associated with the regulation of gluconeogenesis in both groups of animals (Méndez-Lucas et al., 2013; Mommsen, 1986; Suarez and Mommsen, 1987). Such a large transcriptional induction of *pck1* is likely to play an important role in stimulating hepatic glucose production in trout. Less

is known about the regulation of the mitochondrial form of Pepck in fish (*pck2*) or mammals (*PEPCK-M*). Salmonids have 2 mitochondrial Pepck isoforms, but glucagon only affects *pck2a* (downregulation) whereas *pck2b* does not respond to the hormone (Fig. 4). In mammals, *PEPCK-M* potentiates the *PEPCK-C*-driven gluconeogenesis (Méndez-Lucas et al., 2013), but it is not sensitive to glucoregulatory hormones like glucagon and insulin (Stark and Kibbey, 2014). The functional relevance of differential glucagon regulation in these duplicated mitochondrial *pck2* paralogues of rainbow trout is not known and warrants further investigation. Overall, this study reveals that strong transcriptional regulation of cytosolic *pck1* by glucagon greatly contributes to increased hepatic *de novo* gluconeogenesis, as *PEPCK-C* does in mammals (Iynedjian and Salavert, 1984).

### ***Regulation of glycogen phosphorylase***

In trout muscle, glucagon regulates the expression of 2 isoforms of glycogen phosphorylase in opposite ways: it inhibits *pygm* but stimulates *pygb* (Fig. 3). While these results reveal that key enzymes involved in muscle glycogen metabolism are affected at the transcript level, the exact functional roles of these trout isoforms have not been elucidated. Transcript regulation suggests a predominant limitation of glycogenolysis by glucagon, but the measurement of enzyme activities will be needed to test this possibility. In mammalian muscle, insulin strongly decreases glycogen phosphorylase activity (Dimitriadis et al., 2011), and reduces its transcript level (Reynet et al., 1996). This study shows transcript regulation of *pygm* in rainbow trout, and the observed decrease seems to support the idea that insulin mounts a counterregulatory response during the final 2 hours of our experiment. However, insulin infusion failed to alter muscle glycogen phosphorylase activity in a previous

study (Polakof et al., 2010). Overall, this suggests that the measured changes in *pygm* transcript abundance, while indicating some effect on glycogen metabolism, should be interpreted with caution in terms of function.

### ***Glucagon signalling***

Glucagon did not activate PKA substrates and FoxO1 in muscle or liver (Fig. 6). A previous study had shown that the hormone has a weak glycogenolytic effect in muscle and mainly acts on the liver (Polakof et al., 2012). Here, it is unclear why the glucagon signalling pathways were not activated in either tissue. However, several different factors may be responsible including the timing of tissue sampling, post-transcriptional mechanisms, and downregulation of the glucagon receptors. The most likely explanation is that glucagon signalling occurred before the tissues were collected (e.g. sampling 4 h after the onset of glucagon administration may have been too late to catch the effects of glucagon on FoxO1 or PKA substrates, and could have provided enough time for insulin to counter the initial response to glucagon). The changes in glucose fluxes observed within just a few hours may also have been elicited by post-transcriptional activation/inhibition of key enzymes in gluconeogenesis and glycogen metabolism (Brighenti et al., 1991; Mommsen and Moon, 1990; Murat and Plisetskaya, 1977; Puviani et al., 1990). Finally, the lack of effects on glucagon signalling may be associated with an overabundance of circulating glucagon. Several *in vivo* studies in rats, report that high levels of glucagon cause downregulation of glucagon receptors (Dighe et al., 1984; Soman and Felig, 1978; Srikant et al., 1977). The hormone might also regulate glucagon receptor concentration in trout hepatocytes (Navarro and Moon, 1994), as it does in mammals (Horwitz and Gurd, 1988; Santos and Blazquez, 1982).

## Conclusions

This study provides the first *in vivo* measurements of fish glucose fluxes during glucagon administration. It shows that glucagon increases blood glucose concentration by causing a rapid mismatch between  $R_a$  and  $R_d$  glucose that gradually disappears over the duration of the experiment (Figs. 1A and 2C). This hyperglycemia results from: (i) an increase in  $R_a$  glucose induced by the stimulation of gluconeogenesis (possibly through transcriptional activation of *pck1* and glycogen phosphorylase, as well as (ii) a decrease in  $R_d$  glucose via inhibition of glycogen synthase and glycolysis. After 4 h of glucagon administration, both  $R_a$  and  $R_d$  glucose decrease below baseline and converge to the same lower level. This late reduction of glucose fluxes may be caused by a counterregulatory response of insulin, potentially linked to a decrease in *pygm* transcript abundance. Results also show that the three known Pepck isoforms of trout are regulated differently, pointing to a conserved role of transcriptionally regulated cytoplasmic Pepck by glucagon between fish and mammals (Fig. 4). This similarity with mammals does not apply to the mitochondrial form of Pepck because the two trout *pck2* transcripts are differentially affected by glucagon, whereas the equivalent mammalian enzyme (PEPCK-M) does not respond to glucoregulatory hormones. Glycogen phosphorylase isoform transcripts are regulated differently between tissues, but also within muscle. Overall, however, the integrated, multi-organ response to glucagon characterized here only leads to modest changes in glucose fluxes and this is another reason why rainbow trout seem unable to exert tight control over glycemia.

## **Acknowledgements**

We thank Bill Fletcher and Christine Archer for expert care of the animals.

## **Competing interests**

No competing interests declared.

## **Author Contributions**

Author contributions: J.F. and J.-M.W. conception and design of research; J.F. performed experiments; J.F. analyzed data; J.F. and J.-M.W. interpreted results of experiments; J.F. and J.-M.W prepared figures; J.F. drafted manuscript; J.F., J.-M.W., D.J.K and J.A.M. edited and revised manuscript; J.F., J.-M.W., D.J.K. and J.A.M. approved final version of manuscript.

## **Funding**

This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada to Jean-Michel Weber (NSERC discovery grant 105639-2012) and to Jan Mennigen (NSERC discovery grant 2114456-2017) and Canadian Foundation for Innovation John Evans Leader's fund 148035).

## References

- Band, G. and Jones, C. T.** (1980). Activation by glucagon of glucose 6-phosphatase activity in the liver of the foetal guinea pig: Portland Press Limited.
- Beale, E., Andreone, T., Koch, S., Granner, M. and Granner, D.** (1984). Insulin and glucagon regulate cytosolic phosphoenolpyruvate carboxykinase (GTP) mRNA in rat liver. *Diabetes* **33**, 328-332.
- Berthelot, C., Brunet, F., Chalopin, D., Juanchich, A., Bernard, M., Noël, B., Bento, P., Da Silva, C., Labadie, K. and Alberti, A.** (2014). The rainbow trout genome provides novel insights into evolution after whole-genome duplication in vertebrates. *Nature Communications* **5**, 3657.
- Blackwell, B. G., Brown, M. L. and Willis, D. W.** (2000). Relative Weight (Wr) Status and Current Use in Fisheries Assessment and Management. *Reviews in Fisheries Science* **8**, 1-44.
- Blasco, J., Marimon, I., Viaplana, I. and Fernández-Borrás, J.** (2001). Fate of plasma glucose in tissues of brown trout in vivo: effects of fasting and glucose loading. *Fish Physiology and Biochemistry* **24**, 247-258.
- Brighenti, L., Puviani, A. C., Gavioli, M. E., Fabbri, E. and Ottolenghi, C.** (1991). Interaction of salmon glucagon, glucagon-like peptide, and epinephrine in the stimulation of phosphorylase a activity in fish isolated hepatocytes. *General and comparative endocrinology* **82**, 131-9.
- Choi, K. and Weber, J.-M.** (2015). Pushing the limits of glucose kinetics: how rainbow trout cope with a carbohydrate overload. *J Exp Biol* **218**, 2873-80.
- Choi, K. and Weber, J.-M.** (2016). Coping with an exogenous glucose overload: Glucose kinetics of rainbow trout during graded swimming. *Am J Physiol* **310**, R493-R501.
- Christ, B., Nath, A., Bastian, H. and Jungermann, K.** (1988). Regulation of the expression of the phosphoenolpyruvate carboxykinase gene in cultured rat hepatocytes by glucagon and insulin. *Eur J Biochem* **178**, 373-379.
- Cleveland, B. M. and Weber, G. M.** (2010). Effects of insulin-like growth factor-I, insulin, and leucine on protein turnover and ubiquitin ligase expression in rainbow trout primary myocytes. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* **298**, R341-R350.
- de Celis, S. V.-R., Rojas, P., Gómez-Requeni, P., Albalat, A., Gutiérrez, J., Médale, F., Kaushik, S. J., Navarro, I. and Pérez-Sánchez, J.** (2004). Nutritional assessment of somatotropin function in gilthead sea bream (*Sparus aurata*): concurrent changes in somatotrophic axis and pancreatic hormones. *Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology* **138**, 533-542.

**de la Higuera, M. and Cardenas, P.** (1986). Hormonal effects on gluconeogenesis from (U-14C)glutamate in rainbow trout (*Salmo gairdneri*). *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry* **85**, 517-521.

**Dighe, R., Rojas, F., Birnbaumer, L. and Garber, A.** (1984). Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus. *J Clin Invest* **73**, 1013-1023.

**Dindia, L., Murray, J., Faught, E., Davis, T. L., Leonenko, Z. and Vijayan, M. M.** (2012). Novel Nongenomic Signaling by Glucocorticoid May Involve Changes to Liver Membrane Order in Rainbow Trout. *PLoS ONE* **7**, e46859.

**Eijkelenboom, A. and Burgering, B. M.** (2013). FOXOs: signalling integrators for homeostasis maintenance. *Nature Reviews Molecular Cell Biology* **14**, 83.

**Enes, P., Panserat, S., Kaushik, S. and Oliva-Teles, A.** (2009). Nutritional regulation of hepatic glucose metabolism in fish. *Fish Physiol Biochem* **35**, 519-39.

**Forbes, J. L. I., Kostyniuk, D. J., Mennigen, J. A. and Weber, J.-M.** (2019). Unexpected effects of insulin on glucose disposal explains glucose intolerance of rainbow trout. *Am. J. Physiol. - Regulatory, Integrative and Comparative Physiology* **316**, R387-R394.

**Foster, G. and Moon, T.** (1990). Control of key carbohydrate- metabolizing enzymes by insulin and glucagon in freshly isolated hepatocytes of the Marine teleost *Hemirhamphus americanus*. *Journal of Experimental Zoology* **254**, 55-62.

**Foster, G., Storey, K. and Moon, T.** (1989). The regulation of 6-phosphofructo-1-kinase by insulin and glucagon in isolated hepatocytes of the American eel. *General and comparative endocrinology* **73**, 382-389.

**Furuichi, M. and Yone, Y.** (1981). Change of blood sugar and plasma insulin levels of fishes in glucose tolerance test. *Nippon Suisan Gakkaishi* **47**, 761-764.

**Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R. and Tschöp, M. H.** (2010). The metabolic actions of glucagon revisited. *Nature Reviews Endocrinology* **6**, 689.

**Haman, F., Powell, M. and Weber, J.-M.** (1997a). Reliability of continuous tracer infusion for measuring glucose turnover rate in rainbow trout. *J Exp Biol* **200**, 2557-63.

**Haman, F. and Weber, J.-M.** (1996). Continuous tracer infusion to measure in vivo metabolite turnover rates in trout. *J Exp Biol* **199**, 1157-1162.

**Haman, F., Zwingelstein, G. and Weber, J.-M.** (1997b). Effects of hypoxia and low temperature on substrate fluxes in fish: plasma metabolite concentrations are misleading. *Am J Physiol* **273**, R2046-R2054.

**Heckmann, L.-H., Sørensen, P. B., Krogh, P. H. and Sørensen, J. G.** (2011). NORMA-Gene: a simple and robust method for qPCR normalization based on target gene data. *Bmc Bioinformatics* **12**, 250.

- Hinshaw, L., Mallad, A., Dalla Man, C., Basu, R., Cobelli, C., Carter, R. E., Kudva, Y. C. and Basu, A.** (2015). Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments. *American Journal of Physiology-Endocrinology and Metabolism* **309**, E474-E486.
- Horwitz, E. M. and Gurd, R. S.** (1988). Quantitative analysis of internalization of glucagon by isolated hepatocytes. *Archives of biochemistry and biophysics* **267**, 758-769.
- Ince, B. W.** (1979). Insulin secretion from the in situ perfused pancreas of the European silver eel, *Anguilla anguilla* L. *General and comparative endocrinology* **37**, 533-540.
- Iynedjian, P. B. and Salavert, A.** (1984). Effects of glucagon, dexamethasone and triiodothyronine on phosphoenolpyruvate carboxykinase (GTP) synthesis and mRNA level in rat liver cells. *Eur J Biochem* **145**, 489-497.
- Jiang, G. and Zhang, B. B.** (2003). Glucagon and regulation of glucose metabolism. *American Journal of Physiology-Endocrinology and Metabolism* **284**, E671-E678.
- Lins, P.-E., Wajngot, A., Adamson, U., Vranic, M. and Efendić, S.** (1983). Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia. *Diabetes* **32**, 633-636.
- Liu, J., Plagnes-Juan, E., Geurden, I., Panserat, S. and Marandel, L.** (2017). Exposure to an acute hypoxic stimulus during early life affects the expression of glucose metabolism-related genes at first-feeding in trout. *Scientific reports* **7**, 363.
- Malbon, C. C., Li, S.-y. and Fain, J. N.** (1978). Hormonal activation of glycogen phosphorylase in hepatocytes from hypothyroid rats. *J Biol Chem* **253**, 8820-8825.
- Marandel, L., Seilliez, I., Veron, V., Skiba-Cassy, S. and Panserat, S.** (2015). New insights into the nutritional regulation of gluconeogenesis in carnivorous rainbow trout (*Oncorhynchus mykiss*): a gene duplication trail. *Physiol Genomics* **47**, 253-63.
- Méndez-Lucas, A., Duarte, J. A. G., Sunny, N. E., Satapati, S., He, T., Fu, X., Bermúdez, J., Burgess, S. C. and Perales, J. C.** (2013). PEPCK-M expression in mouse liver potentiates, not replaces, PEPCK-C mediated gluconeogenesis. *Journal of hepatology* **59**, 105-113.
- Mommsen, T. P.** (1986). Comparative gluconeogenesis in hepatocytes from salmonid fishes. *Canadian journal of zoology* **64**, 1110-1115.
- Mommsen, T. P. and Moon, T. W.** (1990). Metabolic response of teleost hepatocytes to glucagon-like peptide and glucagon. *J. Endocrinol.* **126**, 109-118.
- Moon, T. W.** (1998). Glucagon: from hepatic binding to metabolism in teleost fish. *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology* **121**, 27-34.
- Moon, T. W.** (2001). Glucose intolerance in teleost fish: fact or fiction? *Comp Biochem Physiol B Biochem Mol Biol* **129**, 243-9.



**Moon, T. W., Gambarotta, A., Capuzzo, A. and Fabbri, E.** (1997). Glucagon and glucagon-like peptide signaling pathways in the liver of two fish species, the American eel and the black bullhead. *Journal of Experimental Zoology* **279**, 62-70.

**Murat, J. and Plisetskaya, E.** (1977). Effects of glucagon on blood-glucose, liver-glycogen level and synthetase-activity in lamprey and carp. *Comptes rendus des seances de la societe de biologie et de ses filiales* **171**, 1302-1305.

**Navarro, I., Gutierrez, J. and Planas, J.** (1995). Estimates of Fish Glucagon by Heterologous Radioimmunoassay - Antibody Selection and Cross-Reactivities. *Comparative Biochemistry and Physiology C-Pharmacology Toxicology & Endocrinology* **110**, 313-319.

**Navarro, I. and Moon, T.** (1994). Glucagon binding to hepatocytes isolated from two teleost fishes, the American eel and the brown bullhead. *Journal of endocrinology* **140**, 217-227.

**Panserat, S., Skiba-Cassy, S., Seiliez, I., Lansard, M., Plagnes-Juan, E., Vachot, C., Aguirre, P., Larroquet, L., Chavernac, G., Medale, F. et al.** (2009). Metformin improves postprandial glucose homeostasis in rainbow trout fed dietary carbohydrates: a link with the induction of hepatic lipogenic capacities? *Am J Physiol Regul Integr Comp Physiol* **297**, R707-15.

**Petersen, T. D. P., Hochachka, P. W. and Suarez, R. K.** (1987). Hormonal-Control of Gluconeogenesis in Rainbow-Trout Hepatocytes - Regulatory Role of Pyruvate-Kinase. *Journal of Experimental Zoology* **243**, 173-180.

**Pilkis, S., El-Maghrabi, M., McGrane, M., Pilkis, J. and Claus, T.** (1982). Regulation by glucagon of hepatic pyruvate kinase, 6-phosphofructo 1-kinase, and fructose-1, 6-bisphosphatase. In *Fed Proc*, vol. 41, pp. 2623-2628.

**Plisetskaya, E. M.** (1998). Some of my not so favorite things about insulin and insulin-like growth factors in fish. *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology* **121**, 3-11.

**Plisetskaya, E. M. and Mommsen, T. P.** (1996). Glucagon and glucagon-like peptides in fishes. *Int Rev Cytol* **168**, 187-257.

**Polakof, S., Panserat, S., Soengas, J. L. and Moon, T. W.** (2012). Glucose metabolism in fish: a review. *Journal of Comparative Physiology B* **182**, 1015-45.

**Puviani, A. C., Otiolenghi, C., Gavioli, M. E., Fabbri, E. and Brighenti, L.** (1990). Action of glucagon and glucagon-like peptide on glycogen metabolism of trout isolated hepatocytes. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry* **96**, 387-391.

**Santos, A. and Blazquez, E.** (1982). Direct evidence of a glucagon- dependent regulation of the concentration of glucagon receptors in the liver. *Eur J Biochem* **121**, 671-677.

**Seiliez, I., Gutierrez, J., Salmerón, C., Skiba-Cassy, S., Chauvin, C., Dias, K., Kaushik, S., Tesseraud, S. and Panserat, S.** (2010). An in vivo and in vitro

assessment of autophagy-related gene expression in muscle of rainbow trout (*Oncorhynchus mykiss*). *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology* **157**, 258-266.

**Shanghavi, D. S. and Weber, J.-M.** (1999). Effects of sustained swimming on hepatic glucose production of rainbow trout. *J Exp Biol* **202**, 2161-2166.

**Shrayyef, M. Z. and Gerich, J. E.** (2010). Normal glucose homeostasis. In *Principles of diabetes mellitus*, pp. 19-35: Springer.

**Soman, V. and Felig, P.** (1978). Regulation of the glucagon receptor by physiological hyperglucagonaemia. *Nature* **272**, 829.

**Srikant, C. B., Freeman, D., McCorkle, K. and Unger, R. H.** (1977). Binding and biologic activity of glucagon in liver cell membranes of chronically hyperglucagonemic rats. *Journal of Biological Chemistry* **252**, 7434-7438.

**Stark, R. and Kibbey, R. G.** (2014). The mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked? *Biochimica et Biophysica Acta (BBA)-General Subjects* **1840**, 1313-1330.

**Steele, R.** (1959). Influences of glucose loading and of injected insulin on hepatic glucose output. *Annals of the New York Academy of Sciences* **82**, 420-430.

**Striffler, J., Garfield, S., Cardell, E. and Cardell, R.** (1984). Effects of glucagon on hepatic microsomal glucose-6-phosphatase in vivo. *Diabete & metabolisme* **10**, 91-97.

**Suarez, R. K. and Mommsen, T. P.** (1987). Gluconeogenesis in teleost fishes. *Canadian Journal of Zoology* **65**, 1869-1882.

**Sugita, T., Shimeno, S., Ohkubo, Y., Hosokawa, H. and Masumoto, T.** (2001). Response of enzyme activities and metabolic intermediate concentrations to glucagon administration in hepatopancreas and muscle of carp. *Fisheries Science* **67**, 157-162.

**Wasserman, D. H.** (2009). Four grams of glucose. *American Journal of Physiology-Endocrinology and Metabolism* **296**, E11-E21.

**Wasserman, D. H., Kang, L., Ayala, J. E., Fueger, P. T. and Lee-Young, R. S.** (2011). The physiological regulation of glucose flux into muscle in vivo. *The Journal of Experimental Biology* **214**, 254-262.

**Weber, J.-M., Choi, K., Gonzalez, A. and Omlin, T.** (2016). Metabolic fuel kinetics in fish: swimming, hypoxia and muscle membranes. *J Exp Biol* **219**, 250-258.

**Weber, J.-M. and Shanghavi, D. S.** (2000). Regulation of glucose production in rainbow trout: Role of epinephrine *in vivo* and in isolated hepatocytes. *Am J Physiol* **278**, R956-R963.

**Wolfe, R. R.** (1992). Radioactive and stable isotope tracers in biomedicine: Principles and practice of kinetic analysis. New York: Wiley-Liss.

**Table 1:** Mean physical characteristics and hematocrit of the 2 groups of catheterized rainbow trout used (i) for *in vivo* measurements of glucose kinetics or (ii) for tissue measurements of glucagon signalling proteins and gene expression of enzymes. Fulton's condition factor K for all fish was  $1.09 \pm 0.02$  (N=22).

Measurements were made before surgery (for body mass and length) or after recovery from surgery (for hematocrit) to make sure that minimal blood loss occurred during and after surgery. Values are means  $\pm$  s.e.m.

	Glucose kinetics experiments (N=8)	Protein and gene expression experiments (N=14)
Body mass (g)	$350 \pm 16$	$344.4 \pm 15$
Body length (cm)	$31.4 \pm 0.4$	$31.7 \pm 0.4$
Hematocrit (%)	$19.5 \pm 0.3$	$19.5 \pm 0.4$

**Table 2:** Primer sequences and annealing temperatures used for mRNA quantification by real-time RT-PCR. Primers for new assays were designed using NCBI-derived trout mRNA sequences in the Primer 3 algorithm (<http://bioinfo.ut.ee/primer3-0.4.0/>) using standard parameters with the following modifications: Amplicon size: 100-300 bp; Primer size: 19-21 nt; Primer  $T_m$  55-65 °C; Primer GC% 45-55; Maximal self-complementarity: 4; Maximal 3' self-complementarity: 4.


Target	Forward primer sequence (5'3')	Reverse primer sequence (3'5')	Annealing temperature [°C]	Reference
<i>pck1</i>	ACAGGGTGAGGCAGATGTAGG	CTAGTCTGTGGAGGTCTAAGGGC	55	(Marandel et al., 2015)
<i>pck2a</i>	ACAATGAGATGATGTGACTGCA	TGCTCCATCACCTACAACCT	56	(Marandel et al., 2015)
<i>pck2b</i>	AGTAGGAGCAGGGACAGGAT	CCGTTCAAGCAAAGGTTAGGC	59	Designed
<i>g6pase</i>	TAGCCATCATGCTGACCAAG	CAGAAGAACGCCACAGAGT	55	(Panserat et al., 2009)

<i>fbpase</i>	GCTGGACCCTTCCATCGG	CGACATAACGCCCACCATAGG	60	(Panserat et al., 2009)
<i>glut4</i>	GGCGATCGTCACAGGGATTC	AGCCTCCCAAGCCGCTCT T	57	(Panserat et al., 2009)
<i>glut2</i>	GTGGAGAAGGAGGCGCAAGT	GCCACCGACACCATGGTAAA	60	Designed
<i>pygm</i>	CCCGGCTACAGGAACAACAT	ACAGCCTGAATGTAGCCACC	55	Designed
<i>pygb</i>	GTGATCCCTGCAGCTGACTT	TCCTCTACCCTCATGCCGAA	59	Designed
<i>glut1bb</i>	GTGATCCCTGCAGCTGACTT	AGGACATCCATGGCAGCTTG	57	(Liu et al., 2017)
<i>pfk</i>	CGTAGGCATGGTGGGTTCTA	AGCCACAGTGTCTACCCATC	59	Designed

**Table 3:** Initial (baseline) and final values after 4 h of glucagon administration for various parameters of glucose metabolism in rainbow trout. Values are means  $\pm$  s.e.m (N=8). Glucose turnover rate ( $R_t$ ) was obtained with the steady state equation, whereas the rates of appearance ( $R_a$ ) and disposal ( $R_d$ ) were obtained with the non-steady state equations of Steele (Steele, 1959). The effects of glucagon are indicated as \*  $P < 0.01$  or \*\*  $P < 0.001$  (paired t-test).


	Baseline	Final (after 4 h of glucagon infusion)
Glucose ( $\mu\text{mol ml}^{-1}$ )	$8.5 \pm 0.4$	$11.7 \pm 0.4$ **
$R_t$ Glucose ( $\mu\text{mol kg}^{-1} \text{min}^{-1}$ )	$11.5 \pm 1.2$	$10.2 \pm 0.9$
$R_a$ Glucose ( $\mu\text{mol kg}^{-1} \text{min}^{-1}$ )	$10.6 \pm 1.4$	$8.8 \pm 1.3$
$R_d$ Glucose ( $\mu\text{mol kg}^{-1} \text{min}^{-1}$ )	$10.6 \pm 1.4$	$8.8 \pm 1.2$

## Figures




**Fig. 1.** Effects of exogenous glucagon on (A) plasma glucose concentration and (B) glucose specific activity. Values are means  $\pm$  s.e.m (N=8). Open symbols are for baseline values before starting glucagon administration. Means significantly different from baseline are indicated by \* ( $P<0.05$ ).






**Fig. 2.** Effects of glucagon on the glucose fluxes of rainbow trout. Fluxes were either calculated with the steady-state equation [turnover rate ( $R_t$ ), panel A where triangles are for baseline values] or the non-steady-state equations of Steele [glucose disposal ( $R_d$ ) and hepatic glucose production ( $R_a$ ), panel B] (Steele, 1959). Panel C shows the effects of glucagon on the capacity to increase glycemia [ $R_a$  glucose –  $R_d$  glucose]. Values are means  $\pm$  s.e.m. (N=8). Means significantly different from baseline (panels A and B) or significantly different from 0 (panel C) are indicated by \* ( $P<0.05$ ).

White muscle gene expression (fold induction)




**Fig. 3.** Relative effects of glucagon on white muscle mRNA transcript abundance of glycogen phosphorylase brain-associated b (*pygb*), phosphofructokinase (*pfk*), glycogen phosphorylase muscle-associated (*pygm*), glucose transporter 4 (*glut4*), and glucose transporter 1 (*glut1*). Values are means  $\pm$  s.e.m. (N=7 for each group). Means significantly different from control are indicated by \* ( $P<0.05$ ).




**Fig. 4.** Relative effects of glucagon on liver mRNA transcript abundance of 3 isoforms of phosphoenolpyruvate carboxykinase: *pck1*, *pck2a*, and *pck2b*. Values are means  $\pm$  s.e.m. (N=7 for each group). Means significantly different from control are indicated by \* ( $P<0.05$ ) or \*\* ( $P<0.001$ ).

Expression of liver genes (fold induction)




**Fig. 5.** Relative effects of glucagon on liver mRNA transcript abundance of fructose 1,6-bisphosphatase (*fbpase*), glucose-6-phosphatase (*g6pase*), glucose transporter 2 (*glut2*) and glycogen phosphorylase brain-associated (*pygb*). Values are means  $\pm$  s.e.m. (N=7 for each group). Glucagon had no effect ( $P>0.05$ ).



**Fig. 6.** Relative effects of glucagon on the levels of the key signalling proteins, PKA substrates and PFOXO1 in white muscle and liver. For each mean, western blots are given for the phosphorylated protein(s). Values are means  $\pm$  s.e.m. (N=6 for each group). Glucagon had no effect on these proteins ( $P>0.05$ ).





**Fig. S1.** Changes in plasma glucagon concentration caused by the administration of exogenous glucagon in adult rainbow trout during measurements of glucose kinetics. Values are means  $\pm$  s.e.m (N=8). Means significantly higher than baseline are indicated by \* ( $P < 0.05$ ).